MYC and prostate adenocarcinoma: We have also shown that fimepinostat suppresses the activities of Myc and AR, including AR variants resulting from mRNA splicing or structural alterations, by inhibiting HDACs and disrupting the transcription of these genes in prostate adenocarcinoma.